Neurogene, Inc./$NGNE
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Neurogene, Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Ticker
$NGNE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
107
ISIN
US64135M1053
Website
Neurogene, Inc. Metrics
BasicAdvanced
$287M
-
-$4.35
-
-
Price and volume
Market cap
$287M
52-week high
$25.19
52-week low
$6.88
Average daily volume
223K
Financial strength
Current ratio
21.03
Quick ratio
20.761
Long term debt to equity
3.226
Total debt to equity
4.012
Interest coverage (TTM)
-6,403.21%
Profitability
EBITDA (TTM)
-86.461
Gross margin (TTM)
-6,940.76%
Net profit margin (TTM)
-8,742.70%
Operating margin (TTM)
-9,701.19%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-21.97%
Return on equity (TTM)
-34.97%
Valuation
Price to revenue (TTM)
403.762
Price to book
1.03
Price to tangible book (TTM)
1.03
Price to free cash flow (TTM)
-5.242
Free cash flow yield (TTM)
-19.08%
Free cash flow per share (TTM)
-383.27%
Growth
Earnings per share change (TTM)
-524.96%
Neurogene, Inc. News
AllArticlesVideos
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 day ago
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
Business Wire·4 days ago
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neurogene, Inc. stock?
Neurogene, Inc. (NGNE) has a market cap of $287M as of July 05, 2025.
What is the P/E ratio for Neurogene, Inc. stock?
The price to earnings (P/E) ratio for Neurogene, Inc. (NGNE) stock is 0 as of July 05, 2025.
Does Neurogene, Inc. stock pay dividends?
No, Neurogene, Inc. (NGNE) stock does not pay dividends to its shareholders as of July 05, 2025.
When is the next Neurogene, Inc. dividend payment date?
Neurogene, Inc. (NGNE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neurogene, Inc.?
Neurogene, Inc. (NGNE) does not currently have a Beta indicator.